Meiji Holdings: Nikkei POS Alternative Data Report - Oversold But Analysts Too Bullish

Meiji Holdings: Nikkei POS Alternative Data Report -Pricing Recovery Suggests a Little Upside Now

Meiji Holdings: Results Show That Nikkei POS Alternative Data Predicts Product Trends Well

Solid 1Q Results for Meiji Support the Long-Term Margin Expansion Story; Shares Undervalued

Launching Coverage of Meiji With Narrow Moat and Stable Moat Trend Ratings, FVE of JPY 10,600

Probiotic Yogurt Growth Taking a Breather; a New Midterm Profit Guidance Target of JPY 120 Billion

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

<p>Narrow-moat <a href="https://www.smartkarma.com/entities/15996" target="_blank" data-smartkarma-citation="entities:15996:1">Meiji Holdings Co Ltd (2269 JP)</a>'s third-quarter results came in below our estimates and seem to fall short of the firm’s internal targets. Given some positive progress of the probiotic yogurt and new drug sales in the fourth quarter, the company has maintained its full-year guidance. While we are encouraged by the sales recovery of the high-margin probiotic yogurt, a category vital to our thesis of margin expansion, we are concerned that a halt in drug demand prior to the National…</p>

Narrow-moat Meiji Holdings Co Ltd (2269 JP)'s third-quarter results came in below our estimates and seem to fall short of the firm’s internal targets. Given some positive progress of the probiotic yogurt and new drug sales in the fourth quarter, the company has maintained its full-year guidance. While we are encouraged by the sales recovery of the high-margin probiotic yogurt, a category vital to our thesis of margin expansion, we are concerned that a halt in drug demand prior to the National…

Meiji's 3Q Weakness Creating an Attractive Entry Point to Build Long-Term Position